| Year |
Citation |
Score |
| 2023 |
Nelson AJ, Lopes RD, Hong H, Hua K, Slovin S, Tan S, Nilsson J, Bhatt DL, Goodman SG, Evans CP, Clarke NW, Shore ND, Margel D, Klotz LH, Tombal B, et al. Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review. Jacc. Cardiooncology. 5: 613-624. PMID 37969642 DOI: 10.1016/j.jaccao.2023.05.011 |
0.346 |
|
| 2022 |
Golan S, Frumer M, Zohar Y, Rosenbaum E, Yakimov M, Kedar D, Margel D, Baniel J, Steinmetz AP, Groshar D, Domachevsky L, Bernstine H. Neoadjuvant Lu-PSMA-I&T Radionuclide Treatment in Patients with High-risk Prostate Cancer Before Radical Prostatectomy: A Single-arm Phase 1 Trial. European Urology Oncology. PMID 36216740 DOI: 10.1016/j.euo.2022.09.002 |
0.343 |
|
| 2021 |
Keizman D, Frenkel M, Peer A, Kushnir I, Rosenbaum E, Sarid D, Leibovitch I, Mano R, Yossepowitch O, Margel D, Wolf I, Geva R, Dresler H, Rouvinov K, Rapoport N, et al. Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study. Nutrients. 13. PMID 34959847 DOI: 10.3390/nu13124295 |
0.322 |
|
| 2021 |
Lifshitz K, Ber Y, Margel D. Role of Metabolic Syndrome in Prostate Cancer Development. European Urology Focus. PMID 33994167 DOI: 10.1016/j.euf.2021.04.022 |
0.316 |
|
| 2020 |
Segal N, Ber Y, Benjaminov O, Tamir S, Yakimov M, Kedar I, Rosenbaum E, Sela S, Ozalvo R, Shavit-Grievink L, Keder D, Baniel J, Margel D. Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening. Annals of Oncology. 31: 1545-1552. PMID 32958357 DOI: 10.1016/J.Annonc.2020.06.025 |
0.435 |
|
| 2020 |
Margel D, Ber Y, Peer A, Shavit-Grievink L, Pinthus JH, Witberg G, Baniel J, Kedar D, Rosenbaum E. Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist. Prostate Cancer and Prostatic Diseases. PMID 32737420 DOI: 10.1038/S41391-020-0264-9 |
0.436 |
|
| 2020 |
Halstuch D, Ber Y, Kedar D, Golan S, Baniel J, Margel D. Short-Term Outcomes of Active Surveillance for Low-Risk Prostate Cancer Among Men with Germline DNA Repair Gene Mutations. The Journal of Urology. 101097JU000000000000. PMID 32191583 DOI: 10.1097/Ju.0000000000001027 |
0.466 |
|
| 2020 |
Ber Y, Segal N, Tamir S, Benjaminov O, Yakimov M, Sela S, Halstauch D, Baniel J, Kedar D, Margel D. A noninferiority within-person study comparing the accuracy of transperineal to transrectal MRI-US fusion biopsy for prostate-cancer detection. Prostate Cancer and Prostatic Diseases. PMID 31953483 DOI: 10.1038/S41391-020-0205-7 |
0.446 |
|
| 2019 |
Margel D, Peer A, Ber Y, Shavit-Grievink L, Tabachnik T, Sela S, Witberg G, Baniel J, Kedar D, Duivenvoorden WC, Rosenbaum E, Pinthus JH. Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and GnRH-antagonist among patients with advanced prostate-cancer and pre-existing cardiovascular disease. The Journal of Urology. 101097JU000000000000. PMID 31188734 DOI: 10.1097/Ju.0000000000000384 |
0.376 |
|
| 2019 |
Halstuch D, Ber Y, Margel D. Screening, Active Surveillance, and Treatment of Localized Prostate Cancer Among Carriers of Germline BRCA Mutations. European Urology Focus. PMID 31147265 DOI: 10.1016/J.Euf.2019.05.009 |
0.435 |
|
| 2019 |
Margel D, Ber Y, Baniel J. Re: Optimizing Patient's Selection for Prostate Biopsy: A Single Institution Experience with Multi-parametric MRI and the 4Kscore Test for the Detection of Aggressive Prostate Cancer. European Urology. PMID 31056230 DOI: 10.1016/J.Eururo.2019.04.024 |
0.455 |
|
| 2019 |
Halstuch D, Baniel J, Lifshitz D, Sela S, Ber Y, Margel D. Characterizing the learning curve of MRI-US fusion prostate biopsies. Prostate Cancer and Prostatic Diseases. PMID 30842585 DOI: 10.1038/S41391-019-0137-2 |
0.427 |
|
| 2019 |
Margel D, Peer A, Ber Y, Sela S, Shavit Grievink L, Tabachnik T, Witberg G, Baniel J, Kedar D, Duivenvoorden WC, Rosenbaum E, Pinthus JH. Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and antagonist among patients with advanced prostate cancer. Journal of Clinical Oncology. 37: 5015-5015. DOI: 10.1200/Jco.2019.37.15_Suppl.5015 |
0.438 |
|
| 2019 |
Halstuch* D, shenar C, Sela S, Ber Y, Kedar D, Baniel J, Margel D. PD55-01 ACTIVE SURVEILLANCE FOR LOW RISK PROSTATE CANCER AMONG MEN WITH HIGH RISK GENETIC PREDISPOSITION Journal of Urology. 201. DOI: 10.1097/01.Ju.0000557068.56520.D4 |
0.412 |
|
| 2019 |
Margel* D, Ber Y, Sela S, Kedar D, Baniel J. MP36-03 TRANSPERINEAL VS. TRANSRECTAL MRI-US FUSION FOR PROSTATE CANCER DETECTION – A PROSPECTIVE RANDOMIZED STUDY. Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556013.70913.48 |
0.466 |
|
| 2019 |
Margel* D, Sela S, Tamir S, Kedar I, Ber Y, Kedar D, Nadu A, Baniel J. MP30-06 MULTI-PARAMETRIC PROSTATE MRI AS A SCREENING TEST AMONG MALE BRCA CARRIERS Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555862.91525.38 |
0.427 |
|
| 2019 |
Dresler H, Keizman D, Frenkel M, Peer A, Rosenbaum E, Margel D, Sarid D, Kushnir I, Neiman V, Leibovitch I, Rouvinov K, Berger R, Eliaz I. Long term effect of PectaSol-C modified citrus pectin treatment in non-metastatic biochemically relapsed prostate cancer patients: Results of a prospective phase II study European Urology Supplements. 18: e3467. DOI: 10.1016/S1569-9056(19)34628-7 |
0.425 |
|
| 2019 |
Golan S, Sela S, Frumer M, Kedar I, Ber Y, Kedar D, Margel D. Genetic testing for hereditary prostate cancer among men in Israel European Urology Supplements. 18: e1809. DOI: 10.1016/S1569-9056(19)31309-0 |
0.45 |
|
| 2019 |
Halstuch D, Sela S, Ber Y, Kedar D, Baniel J, Margel D. Active surveillance for low risk prostate cancer among men with high risk genetic predisposition European Urology Supplements. 18: e1727. DOI: 10.1016/s1569-9056(19)31252-7 |
0.33 |
|
| 2018 |
Tapiero S, Helfand A, Kedar D, Yossepowitch O, Nadu A, Baniel J, Lifshitz D, Margel D. Patient Compliance with Maintenance Intravesical Therapy for Non-Muscle Invasive Bladder Cancer. Urology. PMID 29792974 DOI: 10.1016/J.Urology.2018.04.039 |
0.307 |
|
| 2018 |
Dresler H, Keizman D, Frenkel M, Peer A, Rosenbaum E, Margel D, Sarid D, Neiman V, Gottfried M, Leibovitch I, Eliaz I. Effect of PectaSol-C modified citrus pectin (P-MCP) treatment (tx) on PSA Dynamics in non- metastatic Biochemically Relapsed Prostate Cancer (BRPC) patients (pts): Results of a prospective Phase II Study European Urology Supplements. 17: e2849. DOI: 10.1016/S1569-9056(18)33726-6 |
0.319 |
|
| 2018 |
Keizman D, Frenkel MA, Peer A, Rosenbaum E, Margel D, Sarid DL, Neiman V, Gottfried M, Maimon N, Leibovitch I, Dresler H, Eliaz I. Effect of pectasol-c modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in non-metastatic biochemically relapsed prostate cancer (BRPC) patients (pts): Results of a prospective phase II study. Journal of Clinical Oncology. 36: 14-14. DOI: 10.1016/S1569-9056(18)33726-6 |
0.347 |
|
| 2018 |
Margel D, Ber Y, Sela S, Belo I, Tabachnik T, Benjaminov O, Tamir S, Baniel J. The learning curve of MRI-US fusion prostate biopsies European Urology Supplements. 17: e1885. DOI: 10.1016/S1569-9056(18)32297-8 |
0.381 |
|
| 2018 |
Shenhar C, Degani H, Bar Y, Baniel J, Tamir S, Binyaminov O, Furman-Haran E, Margel D. Innovative diffusion MRI protocol to improve prostate cancer diagnosis European Urology Supplements. 17: e1883-e1884. DOI: 10.1016/S1569-9056(18)32296-6 |
0.43 |
|
| 2018 |
Margel D, Pe'er A, Ber Y, Shaparberg M, Sela S, Ozalvo R, Tabachnik T, Duivenvoorden W, Pinthus J, Baniel J. MP52-17 CARDIOVASCULAR EVENTS AND BIOMARKERS IN A RANDOMIZED TRIAL COMPARING LHRH AGONIST AND ANTAGONIST AMONG PATIENTS WITH ADVANCED PROSTATE CANCER Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1668 |
0.451 |
|
| 2018 |
Margel D, Ber Y, Sela S, Tabachnik T, Belo I, Tamir S, Benjaminov O, Baniel J. PD23-08 CHARACTERIZING THE LEARNING CURVE OF MRI-US FUSION PROSTATE BIOPSIES Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1189 |
0.348 |
|
| 2017 |
Halstuch D, Baniel J, Lifshitz D, Sela S, Ber Y, Margel D. Assessment of Needle Tip Deflection During Transrectal Guided Prostate Biopsy - Implications for Targeted Biopsies. Journal of Endourology. PMID 29284293 DOI: 10.1089/End.2017.0694 |
0.41 |
|
| 2017 |
Goldberg H, Grievink LS, Mano R, Ber Y, Ozalbo R, Tuval S, Baniel J, Margel D. Is there a difference in testosterone levels and its regulators in men carrying BRCA mutations? Oncotarget. 8: 103843-103850. PMID 29262604 DOI: 10.18632/Oncotarget.21802 |
0.402 |
|
| 2017 |
Goldberg H, Shavit Grievink L, Mano R, Bar Y, Ozalbo R, Tuval S, Baniel J, Margel D. Lower Urinary Tract Symptoms and Benign Prostate Hyperpasia Features among Male BRCA Mutation Carriers. Urology. PMID 28577930 DOI: 10.1016/J.Urology.2017.05.036 |
0.397 |
|
| 2017 |
Keizman D, Frenkel MA, Edwards TM, Rosenbaum E, Margel D, Sarid D, Neiman V, Gottfried M, Maimon N, Leibovitch I, Dresler H, Eliaz I. Effect of PectaSol-C modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in patients (pts) with nonmetastatic, biochemically relapsed prostate cancer (BRPC): Results of the interim analysis of a prospective phase II study. Journal of Clinical Oncology. 35: e16588-e16588. DOI: 10.1200/Jco.2017.35.15_Suppl.E16588 |
0.341 |
|
| 2017 |
Margel D, Peer A, Ber Y, Shaparberg M, Sela S, Ozalvo R, Baniel J, Duivenvoorden W, Pinthus J. MP57-13 EARLY CARDIoVASCULAR MORBIDITY IN A PILOT PROSPECTIVE RANDOMIZED TRIAL COMPARING LHRH AGONIST AND ANTAGONIST AMONG PATIENTS WITH ADVANCED PROSTATE CANCER Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1787 |
0.46 |
|
| 2016 |
Al Edwan G, Bhindi B, Margel D, Chadwick K, Finelli A, Zlotta A, Trachtenberg J, Fleshner N. The association of male pattern baldness and risk of cancer and high-grade disease among men presenting for prostate biopsy. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 10: E424-E427. PMID 28096933 DOI: 10.5489/cuaj.3813 |
0.39 |
|
| 2016 |
Lewin R, Sulkes A, Shochat T, Tsoref D, Rizel S, Liebermann N, Hendler D, Neiman V, Ben-Aharon I, Friedman E, Paluch-Shimon S, Margel D, Kedar I, Yerushalmi R. Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations. Breast Cancer Research and Treatment. 157: 511-6. PMID 27225387 DOI: 10.1007/S10549-016-3836-6 |
0.31 |
|
| 2015 |
Ehrlich Y, Margel D, Lubin MA, Baniel J. Advances in the treatment of testicular cancer. Translational Andrology and Urology. 4: 381-90. PMID 26816836 DOI: 10.3978/J.Issn.2223-4683.2015.06.02 |
0.343 |
|
| 2015 |
Edwan GA, Ghai S, Margel D, Kulkarni G, Hamilton R, Toi A, Haidar MA, Finelli A, Fleshner NE. Magnetic resonance imaging detected prostate evasive anterior tumours: Further insights. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 9: E267-72. PMID 26029293 DOI: 10.5489/Cuaj.2562 |
0.455 |
|
| 2015 |
de Boo L, Pintilie M, Yip P, Baniel J, Fleshner N, Margel D. Time from first detectable PSA following radical prostatectomy to biochemical recurrence: A competing risk analysis. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 9: E14-21. PMID 25624961 DOI: 10.5489/Cuaj.2147 |
0.39 |
|
| 2015 |
Mano R, Baniel J, Shoshany O, Margel D, Bar-On T, Nativ O, Rubinstein J, Halachmi S. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer. Urologic Oncology. 33: 67.e1-7. PMID 25060672 DOI: 10.1016/J.Urolonc.2014.06.010 |
0.34 |
|
| 2015 |
Bhindi B, Locke J, Alibhai SM, Kulkarni GS, Margel DS, Hamilton RJ, Finelli A, Trachtenberg J, Zlotta AR, Toi A, Hersey KM, Evans A, van der Kwast TH, Fleshner NE. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. European Urology. 67: 64-70. PMID 24568896 DOI: 10.1016/j.eururo.2014.01.040 |
0.338 |
|
| 2015 |
Helfand A, Shavit Grievink L, Kedar D, Yossepowitch O, Nadu A, Rosenbaum E, Baniel J, Margel D. PD17-12 PATIENT COMPLIANCE WITH INTRAVESICAL MAINTENANCE PROTOCOLS FOR NON-MUSCLE INVASIVE BLADDER CANCER Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.669 |
0.311 |
|
| 2015 |
Shavit Grievink L, Hoshen M, Feldman B, Balicer R, Baniel J, Rosenbaum E, Margel D. MP32-17 “CHOOSING WISELY” – PROSTATE CANCER SCREENING, DIAGNOSIS, AND TREATMENT AMONG THE ELDERLY MEN IN ISRAEL Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1413 |
0.448 |
|
| 2014 |
Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Baniel J, Fleshner N, Austin PC. Is pathology necessary to predict mortality among men with prostate-cancer? Bmc Medical Informatics and Decision Making. 14: 114. PMID 25495664 DOI: 10.1186/S12911-014-0114-6 |
0.596 |
|
| 2014 |
Bhindi B, Margel D, Hamilton RJ, Fernandes KA, Trottier G, Hersey KM, Finelli A, Trachtenberg J, Zlotta A, Kulkarni GS, Toi A, Evans A, van der Kwast TH, Fleshner NE. The impact of the use of aspirin and other nonsteroidal anti-inflammatory drugs on the risk of prostate cancer detection on biopsy. Urology. 84: 1073-80. PMID 25443907 DOI: 10.1016/J.Urology.2014.05.071 |
0.431 |
|
| 2014 |
Margel D, Benjaminov O, Ozalvo R, Shavit Grievink L, Kedar I, Yerushalmi R, Ben-Aharon I, Neiman V, Yossepowitch O, Kedar D, Levy Z, Shohat M, Brenner B, Baniel J, Rosenbaum E. Personalized prostate cancer screening among men with high risk genetic predisposition- study protocol for a prospective cohort study. Bmc Cancer. 14: 528. PMID 25047061 DOI: 10.1186/1471-2407-14-528 |
0.495 |
|
| 2014 |
Lega IC, Shah PS, Margel D, Beyene J, Rochon PA, Lipscombe LL. The effect of metformin on mortality following cancer among patients with diabetes. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 1974-84. PMID 25030683 DOI: 10.1158/1055-9965.Epi-14-0327 |
0.397 |
|
| 2014 |
Margel D. Metformin to prevent prostate cancer: a call to unite. European Urology. 66: 1021-2. PMID 24908475 DOI: 10.1016/J.Eururo.2014.05.012 |
0.438 |
|
| 2014 |
Cole E, Margel D, Greenspan M, Shayegan B, Matsumoto E, Fischer MA, Patlas M, Daya D, Pinthus JH. Is there a role for anterior zone sampling as part of saturation trans-rectal ultrasound guided prostate biopsy? Bmc Urology. 14: 34. PMID 24884966 DOI: 10.1186/1471-2490-14-34 |
0.467 |
|
| 2014 |
Margel D, Urbach D, Fleshner N, Austin PC. Reply to M.M.J. Zanders et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 702. PMID 24395848 DOI: 10.1200/Jco.2013.53.8728 |
0.423 |
|
| 2014 |
Bhindi B, Margel D, Trottier G, Hamilton RJ, Kulkarni GS, Hersey KM, Finelli A, Trachtenberg J, Zlotta A, Toi A, Evans A, van der Kwast T, Fleshner NE. Obesity is associated with larger prostate volume but not with worse urinary symptoms: analysis of a large multiethnic cohort. Urology. 83: 81-7. PMID 24044911 DOI: 10.1016/J.Urology.2013.07.039 |
0.379 |
|
| 2014 |
Wong LM, Alibhai SM, Trottier G, Timilshina N, Van der Kwast T, Zlotta A, Lawrentschuk N, Kulkarni G, Hamilton R, Ferrara S, Margel D, Trachtenberg J, Jewett MA, Toi A, Evans A, et al. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression. European Urology. 66: 406-13. PMID 23664820 DOI: 10.1016/J.Eururo.2013.04.038 |
0.491 |
|
| 2014 |
Al-Edwan GMA, Bhindi B, Margel D, Chadwick K, Finelli A, Zlotta A, Trachtenberg J. 827 Association of male pattern baldness and risk of cancer and high grade disease among men presenting for prostate biopsy European Urology Supplements. 13. DOI: 10.1016/S1569-9056(14)60815-0 |
0.474 |
|
| 2014 |
Al Edwan G, Margel D, Haidar M, Sangeet.Ghai S, Finelli A, Hamilton R, Kulkarn G, Toi A, Fleshner N. MP53-06 MAGNETIC RESONANCE IMAGING DETECTED PROSTATE EVASIVE ANTERIOR TUMORS: FURTHER INSIGHTS Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1637 |
0.487 |
|
| 2013 |
Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, Fleshner N. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3069-75. PMID 23918942 DOI: 10.1200/Jco.2012.46.7043 |
0.603 |
|
| 2013 |
Margel D, Urbach D, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, Fleshner N. Association between metformin use and risk of prostate cancer and its grade. Journal of the National Cancer Institute. 105: 1123-31. PMID 23853056 DOI: 10.1093/Jnci/Djt170 |
0.61 |
|
| 2013 |
Margel D, Nandy I, Wilson TH, Castro R, Fleshner N. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study. The Journal of Urology. 190: 2039-45. PMID 23820059 DOI: 10.1016/J.Juro.2013.06.051 |
0.443 |
|
| 2013 |
Toren P, Margel D, Kulkarni G, Finelli A, Zlotta A, Fleshner N. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study. Bmj (Clinical Research Ed.). 346: f2109. PMID 23587564 DOI: 10.1136/Bmj.F2109 |
0.449 |
|
| 2013 |
Rosenberg E, Baniel J, Spector Y, Faerman A, Meiri E, Aharonov R, Margel D, Goren Y, Nativ O. Predicting progression of bladder urothelial carcinoma using microRNA expression. Bju International. 112: 1027-34. PMID 23387295 DOI: 10.1111/J.1464-410X.2012.11748.X |
0.358 |
|
| 2013 |
Yap SA, Alibhai SM, Abouassaly R, Timilshina N, Margel D, Finelli A. Ipsilateral adrenalectomy at the time of radical nephrectomy impacts overall survival. Bju International. 111: E54-8. PMID 23039377 DOI: 10.1111/J.1464-410X.2012.11435.X |
0.334 |
|
| 2013 |
Locke J, Hersey K, Margel D, Sorokin K, Fleshner N. Prevalence and predictors of selenium and vitamin E supplementation in a urology population. Journal of Alternative and Complementary Medicine (New York, N.Y.). 19: 128-33. PMID 22985217 DOI: 10.1089/Acm.2011.0184 |
0.354 |
|
| 2013 |
Venkateswaran S, Margel D, Yap S, Hersey K, Yip P, Fleshner NE. Comparison of serum testosterone levels in prostate cancer patients Canadian Urological Association Journal. 6: 183-6. DOI: 10.5489/Cuaj.377 |
0.438 |
|
| 2013 |
Margel D, Urbach DR, Lipscombe L, Bell C, Kilkarni G, Austin P, Joshua AM, Fleshner NE. Metformin use and all-cause and prostate-cancer-specific mortality among diabetic men. Journal of Clinical Oncology. 31: 5007-5007. DOI: 10.1200/Jco.2013.31.15_Suppl.5007 |
0.634 |
|
| 2013 |
Patterson L, Pandya R, Margel D, Hotte SJ, Shayegan B, Mukherjee SD, Pinthus JH. 1441 INCIDENCE, CHARACTERISTICS, AND IMPLICATIONS OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER UNDERGOING CISPLATIN BASED NEO-ADJUVANT CHEMOTHERAPY Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2795 |
0.34 |
|
| 2013 |
Pandya R, Margel D, Patterson L, Hotte SJ, Daya D, Shayegan B, Mukherjee SD, Pinthus JH. 1440 EMERGENCE OF VARIANT HISTOLOGY DURING NEO-ADJUVANT CHEMO-THERAPY FOR MUSCLE INVASIVE URETHELIAL BLADDER CANCER IS COMMON AND ASSOCIATED WITH POOR PROGNOSIS Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2794 |
0.331 |
|
| 2013 |
Bhindi B, Kulkarni G, Margel D, Jiang H, Al-Edwan G, Chadwick K, Trottier G, Fleshner N. 2241 VALIDATION OF SERUM ADIPOKINES FOR PREDICTION OF PROSTATE CANCER IN A PROSPECTIVE COHORT STUDY Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2150 |
0.476 |
|
| 2013 |
Margel D, Urbach D, Lipscombe L, Bell C, Kulkarni G, Austin P, Fleshner N. 344 THE ASSOCIATION BETWEEN METFORMIN USE AND RISK OF PROSTATE CANCER AND GRADE AT PRESENTATION Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1730 |
0.629 |
|
| 2013 |
Bhindi B, Margel D, Hamilton R, Kulkarni G, Al-Edwan G, Finelli A, Toi A, Evans A, van der Kwast T, Chadwick K, Trachtenberg J, Zlotta A, Hersey K, Fleshner N. 341 IMPACT OF METABOLIC SYNDROME ON THE RISK OF PROSTATE CANCER AND HIGH GRADE DISEASE AMONG MEN PRESENTING FOR PROSTATE BIOPSY Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1727 |
0.467 |
|
| 2013 |
Margel D, Fleshner N. The role of 5α-reductase inhibitors (5-ARIs) in prostate cancer chemoprevention Prostate Cancer: a Comprehensive Perspective. 391-394. DOI: 10.1007/978-1-4471-2864-9_32 |
0.347 |
|
| 2012 |
Margel D, Yap S, Lawrentschuk N, Klotz L, Haider MA, Finelli A, Zlotta A, Trachtenberg J, Fleshner NE. Impact of multiparametric endorectal coil prostate MRI on disease reclassification among active surveillance candidates: A prospective cohort study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 30. PMID 28142908 DOI: 10.1200/jco.2012.30.5_suppl.30 |
0.399 |
|
| 2012 |
Margel D, Yap S, Lawrentschuk N, Klotz L, Haider MA, Finelli A, Zlotta A, Trachtenberg J, Fleshner NE. Impact of multiparametric endorectal coil prostate MRI on disease reclassification among active surveillance candidates: A prospective cohort study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 30. PMID 27967849 DOI: 10.1200/Jco.2012.30.5_Suppl.30 |
0.493 |
|
| 2012 |
Elharram M, Margel D, Finelli A, Trachtenberg J, Evans A, van der Kwast TH, Sweet JM, Fleshner N. Perineural invasion on prostate biopsy does not predict adverse pathological outcome. The Canadian Journal of Urology. 19: 6567-72. PMID 23228294 |
0.377 |
|
| 2012 |
Venkateswaran S, Margel D, Yap S, Hersey K, Yip P, Fleshner NE. Comparison of serum testosterone levels in prostate cancer patients receiving LHRH agonist therapy with or without the removal of the prostate. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 6: 183-6. PMID 22664629 DOI: 10.5489/Cuaj.11278 |
0.44 |
|
| 2012 |
Margel D, Fleshner N. The role of 5-alpha-reductase inhibitors in active surveillance. Current Opinion in Urology. 22: 243-6. PMID 22472511 DOI: 10.1097/Mou.0B013E328351Dd57 |
0.391 |
|
| 2012 |
Margel D, Yap SA, Lawrentschuk N, Klotz L, Haider M, Hersey K, Finelli A, Zlotta A, Trachtenberg J, Fleshner N. Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study. The Journal of Urology. 187: 1247-52. PMID 22335871 DOI: 10.1016/J.Juro.2011.11.112 |
0.41 |
|
| 2012 |
Margel D, Bostrom P, Baniel J, Yossepowitch O, Zlotta A, Fleshner N. External validation of a biomarker based pre-cystectomy algorithm to predict nonorgan confined urothelial cancers. The Journal of Urology. 187: 840-4. PMID 22245328 DOI: 10.1016/J.Juro.2011.10.148 |
0.307 |
|
| 2012 |
Margel D, Trottier G, Yap S, Elharram M, Connor M, Bhindi B, Finelli A, Kulkarny G, Fleshner N. 2235 SERUM ADIPOKINE LEVELS IMPROVE PROSTATE CANCER PREDICTION COMPARED TO CLINICAL DATA ONLY Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.2411 |
0.454 |
|
| 2012 |
Fleshner N, Margel D, Wilson TH, Castro R. 2109 UTILITY OF PSA IN THE REDUCTION BY DUTASTERIDE OF CLINICAL PROGRESSION EVENTS IN EXPECTANT MANAGEMENT OF PROSTATE CANCER (REDEEM) STUDY Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.2277 |
0.381 |
|
| 2012 |
Margel D, Venkateswaran S, Darwish A, Finelli A, Trachtenberg J, Chadwick K, Fleshner N. 1451 THE ASSOCIATION BETWEEN MALE PATTERN BALDNESS AND SECOND TO FORTH FINGER RATIO WITH PROSTATE CANCER- A PROSPECTIVE COHORT STUDY Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1945 |
0.466 |
|
| 2012 |
Bostrom PJ, Thoms J, Rhijn BWGv, Ahmed O, Stakhovskyi O, Margel D, Evans A, Mirtti T, Sykes J, Pintillie M, Laato M, Milosevic M, Zlotta AR, Bristow RG. Bladder Cancer: Invasive IModerated Poster1417 HYPOXIA IS INDEPENDENTLY ASSOCIATED WITH POOR OUTCOME IN UROTHELIAL BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY The Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1868 |
0.387 |
|
| 2012 |
Margel D, Elharram M, Finelli A, Zlotta A, Trachtenberg J, Evans A, Fleshner N. 1330 IS PERINEURAL INVASION IN PROSTATE BIOPSIES ASSOCIATED WITH ADVERSE PATHOLOGICAL OUTCOME? OLD PARADIGM REVISITED Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1712 |
0.415 |
|
| 2012 |
Toren P, Margel D, Kulkarni G, Finelli A, Zlotta A, Fleshner N. 1250 THE ROLE OF DUTASTERIDE IN PREVENTING BPH CLINICAL PROGRESSION IN ASYMPTOMATIC MEN WITH AN ENLARGED PROSTATE Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1568 |
0.43 |
|
| 2011 |
Margel D, Baniel J, Wasserberg N, Bar-Chana M, Yossepowitch O. Radiation therapy for prostate cancer increases the risk of subsequent rectal cancer. Annals of Surgery. 254: 947-50. PMID 22107741 DOI: 10.1097/Sla.0B013E3182382Fd5 |
0.433 |
|
| 2011 |
Margel D, Fleshner NE. Oral contraceptive use is associated with prostate cancer: an ecological study. Bmj Open. 1: e000311. PMID 22102643 DOI: 10.1136/Bmjopen-2011-000311 |
0.456 |
|
| 2011 |
Margel D, Alkhateeb SS, Finelli A, Fleshner N. Diminished efficacy of Bacille Calmette-Guérin among elderly patients with nonmuscle invasive bladder cancer. Urology. 78: 848-54. PMID 21840578 DOI: 10.1016/J.Urology.2011.04.070 |
0.35 |
|
| 2011 |
Margel D, Lawrentschuk N, Haider M, Hersey K, Finelli AF, Zlotta A, Trachtenberg J, Fleshner N. 1292 PROSTATE MRI FINDINGS PRIOR TO COMMENCING ACTIVE SURVEILLANCE AMONG MEN WITH LOW RISK PROSTATE CANCER Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.992 |
0.367 |
|
| 2011 |
Trottier G, Connor MK, Zeppieri J, Margel D, Fernandes KA, Finelli A, Evans A, van der Kwast TH, Toi A, Hersey K, Fleshner NE. 2331 ASSOCIATION OF ADIPOKINES WITH PROSTATE CANCER AND HIGH GRADE DISEASE DEPENDS ON BODY MASS INDEX Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.2578 |
0.434 |
|
| 2009 |
Margel D, Harel A, Yossepowitch O, Baniel J. A novel algorithm to improve pathologic stage prediction of clinically organ-confined muscle-invasive bladder cancer. Cancer. 115: 1459-64. PMID 19152435 DOI: 10.1002/Cncr.24138 |
0.324 |
|
| 2009 |
Margel D, Bar-Chana MM, Yossepowitch O, Baniel J. RADIATION THERAPY FOR PROSTATE CANCER INCREASES THE RISK OF RECTAL CANCER The Journal of Urology. 181: 613. DOI: 10.1016/S0022-5347(09)61721-3 |
0.478 |
|
| 2008 |
Margel D, Harel A, Baniel J. A NOVEL ALGORITHM TO IMPROVE STAGE PREDICTION OF CLINICALLY ORGAN-CONFINED INVASIVE BLADDER CANCER Journal of Urology. 179: 578-578. DOI: 10.1016/S0022-5347(08)61699-7 |
0.318 |
|
| 2007 |
Margel D, Tal R, Baniel J. Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer. The Journal of Urology. 178: 2297-300; discussion. PMID 17936837 DOI: 10.1016/J.Juro.2007.08.017 |
0.367 |
|
| 2007 |
Margel D, Lifshitz D, Brown N, Lask D, Livne PM, Tal R. Predictors of nocturia quality of life before and shortly after prostatectomy. Urology. 70: 493-7. PMID 17905104 DOI: 10.1016/J.Urology.2007.05.001 |
0.347 |
|
| 2007 |
Ehrlich Y, Yossepowitch O, Margel D, Lask D, Livne PM, Baniel J. Early Initiation of Aspirin After Prostate and Transurethral Bladder Surgeries is Not Associated With Increased Incidence of Postoperative Bleeding: A Prospective, Randomized Trial Journal of Urology. 178: 524-528. PMID 17570430 DOI: 10.1016/J.Juro.2007.03.134 |
0.327 |
|
| 2006 |
Margel D, Tal R, Neuman A, Konichezky M, Sella A, Baniel J. Prediction of extravesical disease by preoperative serum markers in patients with clinically organ confined invasive bladder cancer. The Journal of Urology. 175: 1253-7; discussion 1. PMID 16515972 DOI: 10.1016/S0022-5347(05)00699-3 |
0.33 |
|
| 2005 |
Yossepowitch O, Lifshitz DA, Dekel Y, Ehrlich Y, Gur U, Margel D, Livne PM, Baniel J. Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation. The Journal of Urology. 173: 890-3. PMID 15711312 DOI: 10.1097/01.Ju.0000147747.89028.64 |
0.323 |
|
| Show low-probability matches. |